Emulex Corporation (NYSE:ELX) yesterday announced the introduction of a comprehensive host-based encryption solution that provides flexible, scalable cost-effective security for data in-flight and at-rest. The solution consists of OneCommand™ Guardian, Emulex's new software security product and OneCommand Key Manager, an enterprise-class, Key management Interoperability Protocol (KMIP) compliant key manager based on IBM Tivoli Key Lifecycle Manager technology, which can be deployed on servers using Emulex's OneSecure™ adapters, or Emulex's family of LightPulse® 8Gb/s Fibre Channel Host Bus Adapters (HBAs).
"With this solution, Emulex is breaking down the cost and complexity barriers that have prevented or delayed security conscious companies from protecting their customers' data with encryption," said Steve Daheb, chief marketing officer and senior vice president of business development, Emulex. "Together with its partners, Emulex is delivering a host-based encryption solution that is less expensive, non-disruptive and more secure than other encryption solutions available in the market today."
- To help enterprises increase data protection and reduce costs associated with data encryption, Compellent will support the new host-based encryption solution announced today by Emulex.
- The Emulex solution includes the OneCommand™ Guardian software security product and OneCommand Key Manager, an enterprise-class, Key Management Interoperability Protocol (KMIP)-compliant key manager.
- The Emulex encryption solution allows customers to adopt a phased deployment of encryption and grow with the customers' businesses as their needs change.
- Compellent customers will be able to convert unencrypted Emulex 8Gb LightPulse® Fibre Channel Host Bus Adapters (HBAs) into encrypted HBAs by adding the Emulex OneCommand Guardian software. HBAs are devices installed in servers to enable the connectivity and transfer of data between the servers and their shared storage.
- Compellent expects to offer Emulex's host-based encryption solution for the Storage Center system in 2011.
Emulex is the leader in converged networking solutions for the data center. Our Connectivity Continuum architecture provides intelligent networking services that transition today's infrastructure into tomorrow's unified network ecosystem. Emulex provides a single framework that intelligently connects every server, network and storage device within the data center.
Through strategic collaboration and integrated partner solutions, Emulex provides its customers with industry leading business value, operational flexibility and strategic advantage. Emulex is listed on the New York Stock Exchange (NYSE:ELX) and has corporate headquarters in Costa Mesa, California. News releases and other information about Emulex Corporation are available at www.emulex.com.
PWRM, Power 3 Medical Products Inc., PWRM.OB has signed a definitive agreement recently to acquire all of the stock of Rozetta-Cell Life Sciences, Inc. Power3 plans to effectuate the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3, with Power3 remaining as the surviving company in the merger.
The acquisition of Rozetta-Cell is expected to be completed in October or November 2010.
Rozetta-Cell is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. The company has a robust intellectual property portfolio and has created numerous products for adult stem cell therapy that are ready for market globally. Rozetta-Cell also has several collaborations in process through which it is partnering with industry-leading adult stem cell research companies and adult stem cell vendors.
Power3 Medical Hits a Grand Slam at ICAD With Four Alzheimer's Poster Presentations
Power3 Medical Products, Inc. announced a few weeks ago that it delivered four poster presentations at the 2010 International Conference on Alzheimer's Disease (NASDAQ:ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro®, Power3's diagnostic test, and focused on Power3's Alzheimer's disease blood serum biomarkers, test and clinical validation trials.
"In preparation for commercialization, our objective at this meeting was to show how Power3's protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimer's disease," said Dr. Ira L. Goldknopf, Power3's President and Chief Scientific Officer.
"It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which Power3's protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs."
About the Company
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases.
Through these processes, Power3 has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s and ALS diseases, for which it is currently engaged in Phase II clinical trials.
These tests are designed to analyze an individual’s proteins to detect the presence of disease, a patient’s disease progression, a patient’s response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.
Tempur-Pedic International Inc. (NYSE:TPX), the leading manufacturer, marketer and distributor of premium mattresses and pillows worldwide, recently announced financial results for the third quarter ended September 30, 2010. The Company also increased full year 2010 financial guidance and expanded its share repurchase authorization.
- Reports Sales Up 32% and EPS Up 82% at $0.62
- Gross Margin Up 340 Basis Points to 51.0% and Operating Margin Up 400 Basis Points to 23.0%
- Raises Financial Guidance for 2010
- Expands Share Repurchase Authorization to $150 Million
Chief Executive Officer Mark Sarvary commented, "We are pleased with the market share gains and the sales and earnings growth we have achieved in the third quarter.
Throughout 2010 we have grown sales and profit while improving our competitive position - strengthening our product line, improving the effectiveness of our marketing and increasing our margins. We continue to project considerable potential for growth for Tempur-Pedic over the coming years, and over the coming quarters we will invest to capitalize on this opportunity."
Tenet Healthcare Corporation (NYSE:THC) recently announced that 43 of its 49 hospitals received 205 quality designations from CIGNA (NYSE:CI), including 71 Center of Excellence (NYSE:COE) designations.
CIGNA uses its COE designations to recognize hospitals for meeting CIGNA HealthCare’s high standards for quality and cost efficiency for procedures and diagnosis. In addition, CIGNA has developed quality designations to indicate superior patient outcomes based on treatment effectiveness for 29 different surgical procedures and medical conditions. The patient outcomes data use hospitals’ Centers for Medicare and Medicaid Services (NYSE:CMS) Hospital Compare measures, Leapfrog Patient Safety Measures, mortality and complication rates in addition to other evidence-based protocol metrics.
Tenet Healthcare Corporation is a health care services company whose subsidiaries and affiliates own and operate acute care hospitals, ambulatory surgery centers and diagnostic imaging centers. Tenet’s hospitals and related health care facilities are committed to providing high quality care to patients in the communities they serve. For more information, please visit www.tenethealth.com.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DoubleInStocks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. (Read more at: http://doubleinstocks.com/disclaimer) Release of Liability: Through use of this website viewing or using, you agree to hold DoubleInStocks.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM).